CNS Summit 2024: Profiling of Drug Response Mechanisms and Patient Sub-populations Through Readouts From a Biobank of Patient-derived Neurons

Profiling of Drug Response Mechanisms and Patient Sub-populations Through Readouts From a Biobank of Patient-derived Neurons

In collaboration with Clexio BioSciences, this study leverages iPSC-derived neurons and a validated AI model to explore antidepressant responses in defined patient populations. The research highlights the potential of esketamine, its major metabolites, and CLE-901-M, a promising pipeline compound, to drive stronger antidepressant effects compared to citalopram. This innovative approach demonstrates the utility of biomarkers in patient-derived neurons to advance drug development and optimize clinical strategies for depression treatment.

Key Highlights:

• Use of patient-derived neurons to predict drug responses and identify sub-populations.

• Esketamine and CLE-901-M showed stronger antidepressant effects than citalopram.

• Individualized insights into patient responses to inform personalized treatment.

‍